Correlation between initial alkaline phosphatase levels and overall survival in newly diagnosed multiple myeloma patients

被引:0
作者
Tan, Jie [1 ,2 ]
Liu, Jun-Peng [3 ]
Yao, Xing-Chen [3 ]
Xu, Zi-Yu [3 ]
Wu, Yue [3 ]
Shi, Xiang-Jun [4 ]
Shi, Ming [3 ]
Li, Meng [3 ]
Du, Xin-Ru [3 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Dept Hematol, Beijing, Peoples R China
[2] Liyuan Community Hlth Serv Ctr, Dept Gen Practice, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Chaoyang Hosp, Dept Orthopaed Surg, 8 Gongti South Rd, Beijing 100020, Peoples R China
[4] Capital Med Univ, Beijing Tiantan Hosp, Dept Rheumatism, Beijing, Peoples R China
关键词
Multiple myeloma (MM); alkaline phosphatase (ALP); survival analysis; liver function; skeletal related event; BIOCHEMICAL MARKERS; BONE-DISEASE; PROGNOSIS; THERAPY;
D O I
10.21037/tcr-24-330
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Alkaline phosphatase (ALP) reflects changes in the condition of multiple myeloma (MM) patients to some extent. However, the relationship of ALP in MM remains uncertain. Our study aimed to determine the association between initial ALP levels and overall survival in newly diagnosed MM patients. Methods: Clinical data from 202 newly diagnosed MM patients at Beijing Chaoyang Hospital between 2012 and 2016 were collected. Baseline characteristics, disease progression staging, serum markers, and patient survival data were recorded. The cut-off value for ALP was calculated based on patient survival data, and patients were divided into groups. Differences in patients' 3- and 5-year survival rates, liver function, bone disease and other indicators among different groups were compared. Independent risk factors influencing newly diagnosed MM patients were identified using COX regression analysis. Results: Patients were categorized into three groups based on ALP cut-off points: Group 1 (ALP <70 U/L), Group 2 (ALP 70 to <120 U/L), and Group 3 (ALP >= 120 U/L). Significant differences were observed in lactate dehydrogenase, serum calcium, white blood cell count, hemoglobin, and liver function indicators (including alanine aminotransferase, aspartate aminotransferase, albumin, and gamma-glutamyl transferase) among different ALP groups (P<0.05). ALP levels varied significantly among patients with different bone disease grades (P<0.05). Median survival times for Groups 1, 2, and 3 were 25, 52, and 31 months, respectively. Group 2 exhibited significantly higher 3-year survival compared to the other two groups (P=0.006), while no significant difference was observed in 5-year survival among the three groups (P=0.51). Age, International Staging System staging, aspartate aminotransferase, beta 2-microglobulin, ALP grading, and severe bone disease were identified as independent factors influencing survival in newly diagnosed patients (P<0.05). Conclusions: ALP levels are correlated with the prognosis of MM patients, and an ALP range of 70 to <120 U/L reflects a better survival expectation.
引用
收藏
页数:14
相关论文
共 40 条
  • [1] Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients
    Alexandrakis, MG
    Passam, FH
    Malliaraki, N
    Katachanakis, C
    Kyriakou, DS
    Margioris, AN
    [J]. CLINICA CHIMICA ACTA, 2002, 325 (1-2) : 51 - 57
  • [2] Myeloma bone disease
    Berenson, JR
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) : 653 - 672
  • [3] Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
    Bernstein, Zachary S.
    Kim, E. Bridget
    Raje, Noopur
    [J]. CELLS, 2022, 11 (15)
  • [4] Alkaline phosphatase: a potential biomarker for stroke and implications for treatment
    Brichacek, Allison L.
    Brown, Candice M.
    [J]. METABOLIC BRAIN DISEASE, 2019, 34 (01) : 3 - 19
  • [5] Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options
    Cetin, Guven
    Eskazan, Ahmet Emre
    Ar, M. Cem
    Aydin, Seniz Ongoren
    Ferhanoglu, Burhan
    Soysal, Teoman
    Baslar, Zafer
    Aydin, Yildiz
    [J]. TURKISH JOURNAL OF HEMATOLOGY, 2014, 31 (04) : 374 - 380
  • [6] Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma
    Cheng, Qianwen
    Zhao, Fei
    Zhang, Bo
    Zhang, Yuyang
    Cai, Li
    Qiao, Bing
    Hu, Yu
    Sun, Chunyan
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [7] Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models
    Cheng, Qianwen
    Cai, Li
    Zhang, Yuyang
    Chen, Lei
    Hu, Yu
    Sun, Chunyan
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] BONEMETASTASIS: MECHANISMS, THERAPIES, AND BIOMARKERS
    Clezardin, Philippe
    Coleman, Rob
    Puppo, Margherita
    Ottewell, Penelope
    Bonnelye, Edith
    Paycha, Frederic
    Confavreux, Cyrille B.
    Holen, Ingunn
    [J]. PHYSIOLOGICAL REVIEWS, 2021, 101 (03) : 797 - 855
  • [9] Corso A, 2001, HAEMATOLOGICA, V86, P394
  • [10] Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
    Dong, Rujiao
    Wang, Yudi
    Sun, Xiaohong
    Lin, Yuanyuan
    Luo, Yuqing
    Xing, Chongyun
    Sun, Lan
    Zhang, Shenghui
    Yu, Kang
    Jiang, Songfu
    Chen, Yi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (12) : 911 - 916